Table 1.

Baseline Characteristics of Pediatric Liver Transplant Recipients, 1990–2010

Characteristic	N=8976
Age in years at liver transplant, median [IQR]	2.3 [0.8, 10.3]
Male sex, n(%)	4318 (48)
Race, n(%)
White	5145 (57)
Black	1621 (18)
Asian	369 (4)
Other	1841 (21)
Year of liver transplant, n(%)
1990–1994	2118 (24)
1995–1999	2209 (25)
2000–2004	2287 (26)
2005–2010	2362 (26)
Primary Cause of Liver Failure, n(%)
Biliary atresia	3453 (39)
Other cholestatic	1193 (13)
Fulminant liver failure	1269 (14)
Metabolic disease*	1240 (14)
Cirrhosis	830 (9)
Tumor	476 (5)
Other	515 (6)
Underlying liver disease with potential kidney involvement**, n(%)	1222 (14)
Living donor, n(%)	1210 (14)
Location at time of liver transplant, n(%)
Hospitalized, intensive care unit	2427 (27)
Hospitalized, non-intensive care unit	1637 (18)
Not hospitalized	4905 (55)
Immunosuppressive therapy at time of transplant, n(%)
Cyclosporine-based	2353 (26)
Tacrolimus-based	5724 (64)
Other	209 (2)
Missing	690 (8)
Documented hepatitis B, n(%)	174 (2)
Documented hepatitis C, n(%)	169 (2)
Pre-transplant serum creatinine mg/dL, median [IQR]	0.4 [0.2, 0.5]
Pre-transplant eGFR ml/min/1.73 m2, median [IQR]***	106.7 [79.8, 139.4]
Pre-transplant eGFR ml/min/1.73 m2, n(%)
≥90	5683 (63)
60–89	1921 (21)
30–59	811 (9)
<30	318 (4)
Missing	243 (3)
Last MELD/PELD score before transplant, median [IQR]	18 [11, 27]

^*Alpha-1 anti-trypsin deficiency, cystic fibrosis, hemochromatosis, homozygous hypercholesterolemia, glycogen storage diseases, maple syrup urine disease, primary hyperoxaluria, tyrosinemia, Wilsons disease, other metabolic

^**Alagilles syndrome, alpha-1 anti-trypsin deficiency, congenital hepatic fibrosis, cystic fibrosis, glycogen storage diseases, primary hyperoxaluria, tyrosinemia, Wilsons disease

^***Using bedside CKiD formula: eGFR=0.413*height (cm)/serum creatinine